PM
SNDX icon

Prosight Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Prosight Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Buy
770,000
+105,000
+16% +$2.28M 2.95% 13
2025
Q4 		$14M Sell
665,000
-338,400
-34% -$5.9M 2.89% 15
2025
Q3 		$15.4M Sell
1,003,400
-76,273
-7% -$998K 3.6% 9
2025
Q2 		$10.1M Buy
1,079,673
+470,421
+77% +$5.18M 2.47% 14
2025
Q1 		$7.48M Sell
609,252
-10,748
-2% -$152K 2.46% 16
2024
Q4 		$8.2M Buy
620,000
+65,897
+12% +$1.13M 2.27% 17
2024
Q3 		$10.7M Buy
554,103
+2,559
+0.5% +$52.9K 2.62% 16
2024
Q2 		$11.3M Buy
+551,544
New +$11.5M 3.38% 10

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Prosight Management's SNDX Position: Q1 2026 in Review

Prosight Management increased its Syndax Pharmaceuticals (SNDX) stake by 16% in Q1 2026, buying an estimated $2.28M and bringing the position to 770,000 shares worth $18M. The position accounts for 2.95% of the portfolio, ranked #13.

Prosight Management first reported a position in SNDX in Q2 2024 and has held it in 8 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Prosight Management held 770,000 shares of Syndax Pharmaceuticals worth $18M as of Q1 2026.
  • Prosight Management bought 105,000 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2.28M.
  • Syndax Pharmaceuticals made up 2.95% of Prosight Management's portfolio in Q1 2026, its #13 holding.
  • Prosight Management first reported a position in Syndax Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.